, Nord-Pas de Calais 691 1990 -1994 64, pp.56-71

S. Corm, , 1999.

, CI: confi dence interval

K. J. Phekoo, M. A. Richards, and H. , Th e incidence and [22] outcome of myeloid malignancies in 2,112 adult patients in southeast England, Osca-Gelis G , Puig-Vives M , Saez M , et al . Population, vol.91, pp.1400-1404, 2006.

, based incidence of myeloid malignancies: fi fteen years of epidemiological data in the province of Girona, Spain, Haematologica, vol.98, pp.95-97, 2013.

O. Visser, A. Trama, and . Maynadi-É-m, Incidence, survival [24] and prevalence of myeloid malignancies in Europe, Eur J Cancer, vol.48, pp.3257-3266, 2012.

M. Maynadi-É, F. Girodon, and I. Manivet-janoray, Twenty-fi ve [25] years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of C ô te d ' Or, Haematologica, vol.96, pp.55-61, 2011.

M. Sant, C. Allemani, and C. Tereanu,

, malignancies in Europe by morphologic subtype: results of the HAEMACARE project, Blood, vol.116, pp.3724-3734, 2010.

A. Monnereau, X. Troussard, and A. Belot, Unbiased estimates of

, long-term net survival of hematological malignancy patients detailed by major subtypes in France, Int J Cancer, vol.132, pp.2378-2387, 2013.

B. J. Druker, F. Guilhot, and S. G. O-'-brien, Five-year follow-up of

, patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, vol.355, pp.2408-2417, 2006.

H. Kantarjian, S. O-'-brien, and E. Jabbour, Improved survival [29] in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience, Blood, vol.119, pp.1981-1987, 2012.

G. Osca-gelis, M. Puig-vives, and M. Saez,

, malignancies really improving? A retrospective 15-year populationbased study, Leuk Lymphoma, 2014.

H. Brenner, A. Gondos, and D. Pulte,

, survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level, Haematologica, vol.93, pp.1544-1549, 2008.

G. Gugliotta, F. Castagnetti, and F. Palandri, Frontline imatinib [32] treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party, Blood, vol.117, pp.5591-5599, 2011.

M. Bj-Ö-rkholm, L. Ohm, and S. Eloranta, Success story of targeted [33] therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to, J Clin Oncol, vol.29, pp.2514-2520, 2008.

C. L. Wiggins, L. C. Harlan, and H. E. Nelson, Age disparity in the [34] dissemination of imatinib for treating chronic myeloid leukemia, Am J Med, vol.123, pp.764-765, 2010.

F. Effi-cace, M. Baccarani, and M. Breccia, Health-related quality

, of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population, Blood, vol.118, pp.4554-4560, 2011.

D. T. Yeung and T. P. Hughes, Th erapeutic targeting of BCR-ABL

, prognostic markers of response and resistance mechanism in chronic myeloid leukaemia, Crit Rev Oncog, vol.17, pp.17-30, 2012.

D. Verma, H. Kantarjian, and S. S. Strom, Malignancies occurring [37] during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies, Blood, vol.118, pp.4353-4358, 2011.

J. Voglova, J. Muzik, and E. Faber, Incidence of second malignancies [38] during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia, Neoplasma, vol.58, pp.256-262, 2011.

P. Rebora, K. Czene, and L. Antolini, Are chronic myeloid leukemia [39] patients more at risk for second malignancies? A population-based study, Am J Epidemiol, vol.172, pp.1028-1033, 2010.

D. Chihara, H. Ito, and T. Matsuda, Decreasing trend in mortality of

, chronic myelogenous leukemia patients after introduction of imatinib in Japan and the, Oncologist, vol.17, pp.1547-1550, 2012.

J. W. Vardiman, J. Th-iele, and D. A. Arber,

, World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, pp.937-951, 2009.

F. Onida, G. Ball, and H. M. Kantarjian, Characteristics and [42] outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia, Cancer, vol.95, pp.1673-1684, 2002.

A. Fabarius, A. Leitner, and A. Hochhaus,

, cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV, Blood, vol.118, pp.6760-6768, 2011.

R. Nowell and P. C. , Th e minute chromosome (Phl) in chronic granulocytic

, leukemia . Blut, vol.8, pp.65-66, 1962.

G. J. Arkesteijn, A. C. Martens, and A. Hagenbeek, Bivariate fl ow karyotyping

, in human Philadelphia-positive chronic myelocytic leukemia, Blood, vol.72, pp.282-286, 1988.

C. F. Verschraegen, M. Talpaz, and C. F. Hirsch-ginsberg, Quantifi cation

, of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia, Blood, vol.85, pp.2705-2710, 1995.

, leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists ' Collaborative Group, J Natl Cancer Inst, vol.89, pp.1616-1620, 1997.

R. Clift and F. Appelbaum, Th omas E . Treatment of chronic myeloid

, leukemia by marrow transplantation, Blood, vol.82, pp.1954-1956, 1993.

J. Moreb, T. Johnson, and P. Kubilis,

, with chronic myelogenous leukemia undergoing allogeneic bone marrow transplantation, Am J Hematol, vol.50, pp.304-306, 1995.

B. Druker, Signal transduction inhibition: results from phase

, I clinical trials in chronic myeloid leukemia . Semin Hematol, vol.38, pp.9-14, 2001.

S. G. O-'-brien, F. Guilhot, and R. A. Larson,

H. M. Kantarjian, S. O-'-brien, and J. Cortes, interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, vol.348, pp.994-1004, 2003.

, improves survival in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase, Cancer, vol.98, pp.2636-2642, 2003.

E. Jabbour, J. Cortes, and H. Kantarjian, Nilotinib for the treatment

, of chronic myeloid leukemia: an evidence-based review, Core Evid, vol.4, pp.207-213, 2010.

H. Kantarjian, N. P. Shah, and A. Hochhaus, Dasatinib versus

, imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, vol.362, pp.2260-2270, 2010.

F. J. Giles, G. Rosti, and P. Beris, Nilotinib is superior to imatinib

, as fi rst-line therapy of chronic myeloid leukemia: the ENESTnd study, Expert Rev Hematol, vol.3, pp.665-673, 2010.

C. Percy, V. Van-holten, and C. Muir, International Classifi cation of

, Geneva: World Health Organization, Diseases for Oncology

A. Fritz, C. Percy, and A. Jack, International Classifi cation of

, Geneva: World Health Organization, Diseases for Oncology

J. Bouyer, D. Cordier, and S. , Epid é miologie -principes et

. Paris, É ditions Inserm ; 1993 . Estimation de la population au 1er janvier par r é gion, 1990.

, ), sexe et â ge (quinquennal, classes d ' â ge), 1990.

. Paris, Institut national de la statistique et des é tudes é conomiques

, Available from: www.insee.fr/fr/themes/detail, asp?ref_id ? e stim-pop & reg_id ?, p.99, 2012.

J. Waterhouse, P. Correa, and C. Muir, Lyon: IARC, Cancer incidence [17] in fi ve continents, vol.III, 1976.

M. Segi, Cancer mortality for selected sites in 24 countries, vol.18, pp.1950-57, 1960.

(. Usa, ). , and M. , Available from: www.mortality.org; www.humanmortality.de Pohar M , Stare J . Relative survival analysis in R, Comput Methods

, Programs Biomed, vol.81, pp.272-278, 2006.

S. Corm, L. Roche, and J. Micol, Changes in the dynamics of the [21] excess mortality rate in chronic phase-chronic myeloid leukemia over 1990 -2007: a population study, Blood, vol.118, pp.4331-4337, 2011.